secwatch.observer — SEC 8-K summary
======================================

Issuer:     ASSEMBLY BIOSCIENCES, INC. (ASMB)
CIK:        0001426800
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0000950170-24-038044
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assembly Bio reports FY 2023 net loss of $61.2M; cash of $130.2M; outlines 2024 milestones
--------------------------------------------------------------------------------

- Cash, equivalents and marketable securities $130.2M as of Dec 31, 2023, up from $91.6M at end of 2022; funded into H2 2025.
- Revenue from collaborations $7.2M in FY 2023 (vs $0 in 2022), primarily from Gilead partnership.
- R&D expenses $48.9M (down from $70.0M); net loss $61.2M ($13.38/share) vs $93.1M ($23.08) in 2022.
- Phase 1a interim data for HSV drug ABI-5366 expected Q3 2024; Phase 1b data for HBV drug ABI-4334 by end of 2024.
- Entered long-term partnership with Gilead and appointed Anuj Gaggar as CMO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1426800/000095017024038044/0000950170-24-038044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1426800/000095017024038044/asmb-20240328.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-038044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer